| 
			
			 A group of graduate students in a spring-semester 
			Bioinformatics and Systems Biology class at Illinois tracked the 
			mutation rate in the virus’s proteome – the collection of proteins 
			encoded by genetic material – through time, starting with the first 
			SARS-CoV-2 genome published in January and ending more than 15,300 
			genomes later in May. 
 The team found some regions still actively spinning off new 
			mutations, indicating continuing adaptation to the host environment. 
			But the mutation rate in other regions showed signs of slowing, 
			coalescing around single versions of key proteins.
 
 “That is bad news. The virus is changing and changing, but it is 
			keeping the things that are most useful or interesting for itself,” 
			says Gustavo Caetano-Anolles, professor of bioinformatics in the 
			Department of Crop Sciences at Illinois and senior author on the 
			study.
 
			
			 
			
 Importantly, however, the stabilization of certain proteins could be 
			good news for the treatment of COVID-19.
 
 According to first author Tre Tomaszewski, a doctoral student in the 
			School of Information Sciences at Illinois, “In vaccine development, 
			for example, you need to know what the antibodies are attaching to. 
			New mutations could change everything, including the way proteins 
			are constructed, their shape. An antibody target could go from the 
			surface of a protein to being folded inside of it, and you can't get 
			to it anymore. Knowing which proteins and structures are sticking 
			around will provide important insights for vaccines and other 
			therapies.”
 
 The research team documented a general slowdown in the virus’s 
			mutation rate starting in April, after an initial period of rapid 
			change. This included stabilization within the spike protein, those 
			pokey appendages that give coronaviruses their crowned appearance.
 
 Within the spike, the researchers found that an amino acid at site 
			614 was replaced with another (aspartic acid to glycine), a mutation 
			that took over the entire virus population during March and April.
 
 “The spike was a completely different protein at the very beginning 
			than it is now. You can barely find that initial version now,” 
			Tomaszewski says.
 
 The spike protein, which is organized into two main domains, is 
			responsible for attaching to human cells and helping inject the 
			virus’s genetic material, RNA, inside to be replicated. The 614 
			mutation breaks an important bond between distinct domains and 
			protein subunits in the spike.
 
 “For some reason, this must help the virus increase its spread and 
			infectivity in entering the host. Or else the mutation wouldn’t be 
			kept,” Caetano-Anolles says.
 The 614 
			mutation was associated with increased viral loads and higher 
			infectivity in a previous study, with no effect on disease severity. 
			Yet, in another study, the mutation was linked with higher case 
			fatality rates.  
            [to top of second column] | 
            
			 
            Tomaszewski says although its role in virulence needs 
			confirmation, the mutation clearly mediates entry into host cells 
			and therefore is critical for understanding virus transmission and 
			spread. 
 Remarkably, sites within two other notable proteins also became more 
			stable starting in April, including the NSP12 polymerase protein, 
			which duplicates RNA, and the NSP13 helicase protein, which 
			proofreads the duplicated RNA strands.
 
 “All three mutations seem to be coordinated with each other,” 
			Caetano-Anolles says. “They are in different molecules, but they are 
			following the same evolutionary process.”
 
 The researchers also noted regions of the virus proteome becoming 
			more variable through time, which they say may give us an indication 
			of what to expect next with COVID-19. Specifically, they found 
			increasing mutations in the nucleocapsid protein, which packages the 
			virus’s RNA after entering a host cell, and the 3a viroporin 
			protein, which creates pores in host cells to facilitate viral 
			release, replication, and virulence.
 
 The research team says these are regions to watch, because 
			increasing non-random variability in these proteins suggests the 
			virus is actively seeking ways to improve its spread. Caetano-Anolles 
			explains these two proteins interfere with how our bodies combat the 
			virus. They are the main blockers of the beta-interferon pathway 
			that make up our antiviral defenses. Their mutation could explain 
			the uncontrolled immune responses responsible for so many COVID-19 
			deaths.
 
 “Considering this virus will be in our midst for some time, we hope 
			the exploration of mutational pathways can anticipate moving targets 
			for speedy therapeutics and vaccine development as we prepare for 
			the next wave,” Tomaszewski says. “We, along with thousands of other 
			researchers sequencing, uploading, and curating genome samples 
			through the GISAID Initiative, will continue to keep track of this 
			virus.”
 
 
            
			 
            
			The article, “New pathways of mutational change in SARS-CoV-2 
			proteomes involve regions of intrinsic disorder important for virus 
			replication and release,” is published on the preprint server 
			BioRxiv [DOI: 10.1101/2020.07.31.231472]. Authors include Tre 
			Tomaszewski, Ryan S. DeVries, Mengyi Dong, Gitanshu Bhatia, Miles D. 
			Norsworthy, Xuying Zheng, and Gustavo Caetano-Anolles.
 
 The Department of Crop Sciences is in the College of Agricultural, 
			Consumer and Environmental Sciences at the University of Illinois.
 
            [Sources: Gustavo Caetano-Anolles,
			Tre Tomaszewski
 News writer: Lauren Quinn]
 |